MX2020010651A - Regímenes de dosificación para el tratamiento de trastornos proliferativos. - Google Patents
Regímenes de dosificación para el tratamiento de trastornos proliferativos.Info
- Publication number
- MX2020010651A MX2020010651A MX2020010651A MX2020010651A MX2020010651A MX 2020010651 A MX2020010651 A MX 2020010651A MX 2020010651 A MX2020010651 A MX 2020010651A MX 2020010651 A MX2020010651 A MX 2020010651A MX 2020010651 A MX2020010651 A MX 2020010651A
- Authority
- MX
- Mexico
- Prior art keywords
- treatment
- proliferative disorders
- dosage regimens
- curcuminoids
- effective amount
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
- A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Dispersion Chemistry (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862655095P | 2018-04-09 | 2018-04-09 | |
| PCT/US2019/024495 WO2019199469A1 (en) | 2018-04-09 | 2019-03-28 | Dosing regimens for treatment of proliferative disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020010651A true MX2020010651A (es) | 2021-01-15 |
Family
ID=68164516
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020010651A MX2020010651A (es) | 2018-04-09 | 2019-03-28 | Regímenes de dosificación para el tratamiento de trastornos proliferativos. |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US11813356B2 (https=) |
| EP (1) | EP3773529B1 (https=) |
| JP (2) | JP7241426B2 (https=) |
| KR (2) | KR20240027843A (https=) |
| CN (1) | CN112272555A (https=) |
| AU (1) | AU2019250832B2 (https=) |
| CA (1) | CA3096591C (https=) |
| ES (1) | ES3061642T3 (https=) |
| MX (1) | MX2020010651A (https=) |
| TW (1) | TWI737974B (https=) |
| WO (1) | WO2019199469A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI737974B (zh) | 2018-04-09 | 2021-09-01 | 美商標徑製藥公司 | 用於治療增生性失調的劑量方案 |
| EP4675742A1 (en) | 2023-02-28 | 2026-01-07 | Panasonic Intellectual Property Management Co., Ltd. | Non-aqueous electrolyte secondary battery |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7244448B2 (en) * | 2000-06-30 | 2007-07-17 | Tekmira Pharmaceuticals Corporation | Liposomal antineoplastic drugs and uses thereof |
| US8563525B2 (en) * | 2004-01-12 | 2013-10-22 | Natrogen Therapeutics International, Inc. | Methods of treating an inflammatory-related disease |
| US7968115B2 (en) * | 2004-03-05 | 2011-06-28 | Board Of Regents, The University Of Texas System | Liposomal curcumin for treatment of cancer |
| US8784881B2 (en) * | 2004-03-05 | 2014-07-22 | Board Of Regents, The University Of Texas System | Liposomal curcumin for treatment of diseases |
| CN1973834A (zh) * | 2006-12-15 | 2007-06-06 | 中国科学院长春应用化学研究所 | 姜黄素用于制备治疗恶性肿瘤耐药的逆转药物的应用 |
| PT2146721E (pt) | 2007-05-15 | 2013-07-18 | Otsuka Pharma Co Ltd | Métodos de utilização de antagonistas da vasopressina com agentes quimioterapeuticos de antraciclina para reduzir a cardiotoxicidade e/ou melhorar a sobrevivência |
| CN101766619B (zh) * | 2008-12-30 | 2011-08-24 | 武汉大学 | 一种治疗恶性肿瘤的药物组合物及应用 |
| EP2501372A4 (en) * | 2009-11-19 | 2013-04-10 | Signpath Pharma Inc | INTRAVENOUS INFUSION OF CURCUMIN AND CALCIUM CHANNEL BLOCKER |
| US9170257B2 (en) | 2012-06-14 | 2015-10-27 | Signpath Pharma Inc. | Method and system for measuring the pharmacokinetics of liposomal curcumin and its metabolite tetrahydrocurcumin |
| DE112013004278T5 (de) * | 2012-08-31 | 2015-05-21 | Signpath Pharma Inc. | Curcumin-Er, ein liposomales PLGA-Nanocurcumin mit verlängerter oder verzögerter Freisetzung zur Minimierung der QT-Verlängerung für eine Krebstherapie |
| US20150147385A1 (en) * | 2013-11-22 | 2015-05-28 | Signpath Pharma, Inc. | Intravenous synthetic curcumin (s-curcumin) for the treatment of proliferative disorders |
| JP6895252B2 (ja) * | 2013-12-18 | 2021-06-30 | サインパス ファルマ, インク.Signpath Pharma, Inc. | 心筋ｉｋｒチャネルの薬剤誘発性阻害のリポソームによる軽減 |
| KR101755245B1 (ko) | 2015-08-12 | 2017-07-07 | 연세대학교 원주산학협력단 | 단량체 염을 이용한 폴리이미드 복합체 제조방법 |
| CA2940470C (en) * | 2015-09-18 | 2019-08-20 | Signpath Pharma Inc. | Treatment for glioblastoma |
| TWI737974B (zh) | 2018-04-09 | 2021-09-01 | 美商標徑製藥公司 | 用於治療增生性失調的劑量方案 |
-
2019
- 2019-03-27 TW TW108110582A patent/TWI737974B/zh active
- 2019-03-28 CN CN201980037784.6A patent/CN112272555A/zh active Pending
- 2019-03-28 ES ES19785177T patent/ES3061642T3/es active Active
- 2019-03-28 EP EP19785177.7A patent/EP3773529B1/en active Active
- 2019-03-28 WO PCT/US2019/024495 patent/WO2019199469A1/en not_active Ceased
- 2019-03-28 JP JP2020555189A patent/JP7241426B2/ja active Active
- 2019-03-28 MX MX2020010651A patent/MX2020010651A/es unknown
- 2019-03-28 KR KR1020247004962A patent/KR20240027843A/ko not_active Withdrawn
- 2019-03-28 US US17/045,431 patent/US11813356B2/en active Active
- 2019-03-28 CA CA3096591A patent/CA3096591C/en active Active
- 2019-03-28 AU AU2019250832A patent/AU2019250832B2/en active Active
- 2019-03-28 KR KR1020207031775A patent/KR102637598B1/ko active Active
-
2022
- 2022-12-22 JP JP2022205330A patent/JP2023030106A/ja active Pending
-
2023
- 2023-10-04 US US18/480,678 patent/US12551436B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| ES3061642T3 (en) | 2026-04-06 |
| CA3096591C (en) | 2023-06-27 |
| JP7241426B2 (ja) | 2023-03-17 |
| US20240050372A1 (en) | 2024-02-15 |
| AU2019250832B2 (en) | 2022-10-27 |
| CN112272555A (zh) | 2021-01-26 |
| US11813356B2 (en) | 2023-11-14 |
| EP3773529C0 (en) | 2025-12-24 |
| EP3773529A1 (en) | 2021-02-17 |
| EP3773529B1 (en) | 2025-12-24 |
| TWI737974B (zh) | 2021-09-01 |
| JP2023030106A (ja) | 2023-03-07 |
| KR102637598B1 (ko) | 2024-02-16 |
| AU2019250832A1 (en) | 2020-10-29 |
| JP2021521130A (ja) | 2021-08-26 |
| WO2019199469A1 (en) | 2019-10-17 |
| TW201946613A (zh) | 2019-12-16 |
| KR20240027843A (ko) | 2024-03-04 |
| US12551436B2 (en) | 2026-02-17 |
| KR20200141062A (ko) | 2020-12-17 |
| US20210161815A1 (en) | 2021-06-03 |
| EP3773529A4 (en) | 2021-12-22 |
| CA3096591A1 (en) | 2019-10-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX393855B (es) | Terapia de combinación que comprende un inhibidor de raf y trametinib | |
| EA201691454A1 (ru) | Композиции придопидина модифицированного высвобождения | |
| CO2019006292A2 (es) | Composiciones de aminoácidos y métodos para el tratamiento de enfermedades y trastornos musculares | |
| MX2020008258A (es) | Formulaciones pediátricas de niraparib y métodos de tratamiento pediátricos. | |
| CY1124532T1 (el) | Δοσολογικα σχηματα για συζευγματα φαρμακου-αντισωματος αντι-tf | |
| BR112015021371A2 (pt) | uso de agonistas de receptor de formil peptídeo 2 para tratar doenças inflamatórias oculares | |
| MX2017010982A (es) | Uso de pridopidina para mejorar la funcion cognitiva y para tratamiento de enfermedad de alzheimer. | |
| MX2018003331A (es) | Administracion de potenciadores de regulador de la conductancia transmembrana de fibrosis quistica (cftr) deuterados. | |
| MX2017005875A (es) | Metodos para tratar enfermedades oculares. | |
| MX2019003173A (es) | Terapia de combinacion con agonistas de peptido natriuretico tipo c (cnp) de liberacion controlada. | |
| FI3493812T3 (fi) | Imetelstaatin ja venetoklaksin yhdistelmiä akuutin myelooisen leukemian hoitoa varten | |
| CY1125384T1 (el) | Συνθεση και φαρμακευτικα προϊοντα για μειωση τοπικου λιπους και σωματικου βαρους και η χρηση αυτων | |
| MX386613B (es) | El uso de un péptido timosina alfa y un inhibidor de pd-1 para el tratamiento de cáncer o una metástasis de este en un sujeto. | |
| MX2017006938A (es) | Terapia de combinacion para el tratamiento de cancer. | |
| EA202090276A1 (ru) | Фармацевтическая композиция для лечения анемии | |
| UY38948A (es) | Régimen de dosificación para agentes anti-dll3 | |
| PT3762015T (pt) | Guselkumab para utilização no tratamento da doença de crohn com um regime de dosagem | |
| PH12020551726A1 (en) | Treatment of atopic dermatitis | |
| BR112015019564A2 (pt) | tratamento de esclerose múltipla com laquinimod | |
| MD20170025A2 (ro) | Tratamente terapeutice pe bază de anamorelin | |
| MX395613B (es) | COMPOSICIONES DE ZINC-y-PGA Y MÉTODOS PARA TRATAR EL CANCER. | |
| MX389282B (es) | Composiciones y métodos para tratar sinucleinopatías. | |
| HK1252514A1 (zh) | 包含与抗体组合施予的ido抑制剂的肿瘤治疗剂 | |
| AR091724A1 (es) | Tratamiento de la esclerosis multiple con una combinacion de laquinimod y fampridina, composicion farmaceutica | |
| MX2020010651A (es) | Regímenes de dosificación para el tratamiento de trastornos proliferativos. |